ANN ARBOR, Mich., April 23, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report first quarter 2025 financial results before the market opens on Tuesday, May 6 ...

ANN ARBOR, Mich., April 24, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the Company plans to highlight new research supporting its lead development candidates for the ...

ANN ARBOR, Mich., April 23, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report first quarter 2025 financial results before the market opens on Tuesday, May 6, 2025.

April 24, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the Company plans to highlight new research supporting its lead development candidates for the treatment of primary ...

ANN ARBOR, Mich. - Esperion Therapeutics (NASDAQ:ESPR) announced today its latest research on development candidates targeting primary sclerosing cholangitis (PSC), a rare liver disease. The ...

ANN ARBOR, Mich. - Esperion Therapeutics (NASDAQ:ESPR) announced today its latest research on development candidates targeting primary sclerosing cholangitis (PSC), a rare liver disease.

April 24, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the Company plans to highlight new research supporting its lead development candidates for the treatment of primary ...

Esperion Therapeutics (NASDAQ:ESPR – Free Report) had its price objective lowered by The Goldman Sachs Group from $4.00 to $3.00 in a research report report published on Thursday morning ...